Aims and Scope of Expert Opinion on Emerging Drugs
Expert Opinion on Emerging Drugs is a quarterly peer-reviewed medical journal publishing structured reviews on drugs/drug classes emerging onto the market across all therapy areas. Each review includes an "expert opinion" section, in which authors are asked to provide their personal view on the current status and future direction of the research discussed. It was established as Emerging Drugs in 1996, changing to its current name in 2001. It is published by Informa. According to the Journal Citation Reports, the journal has a 2014 impact factor of 3.058. Less
Key Metrics
CiteScore 

5.6
Eigenfactor 

0.001 - 0.005
H-Index 

52
Impact Factor 

< 5
SJR 

Q1Pharmacology

SNIP 

0.8
Recommended pre-submission checks
Powered by 

Topics Covered on Expert Opinion on Emerging Drugs
Expert Opinion on Emerging Drugs Journal Specifications
| Overview | |
| Publisher | TAYLOR & FRANCIS LTD |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 2001 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Expert Opinion on Emerging Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Expert Opinion on Emerging Drugs
PROTAC degraders for lymphoid malignancies - current status and future directions.
- 23 Oct 2026
- Expert opinion on emerging drugs
Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape
- 15 Oct 2026
- Expert Opinion on Emerging Drugs
Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options
- 5 Oct 2026
- Expert Opinion on Emerging Drugs
Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra
- 30 Sep 2026
- Expert Opinion on Emerging Drugs
Emerging drugs for diabetic macular edema: an update
- 25 Sep 2026
- Expert Opinion on Emerging Drugs
Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics
- 11 Sep 2026
- Expert Opinion on Emerging Drugs
PROTAC degraders for lymphoid malignancies - current status and future directions.
- 23 Oct 2026
- Expert opinion on emerging drugs
Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape
- 15 Oct 2026
- Expert Opinion on Emerging Drugs
Emerging therapies for pericarditis: from anti-IL-1 agents to novel therapeutic options
- 5 Oct 2026
- Expert Opinion on Emerging Drugs
Targeted oral peptide therapy for inflammatory bowel disease: focus on the IL-23 receptor antagonist icotrokinra
- 30 Sep 2026
- Expert Opinion on Emerging Drugs
Emerging drugs for diabetic macular edema: an update
- 25 Sep 2026
- Expert Opinion on Emerging Drugs
Recent advances in hidradenitis suppurativa therapeutics: a focus on existing and future medical therapeutics
- 11 Sep 2026
- Expert Opinion on Emerging Drugs